» Articles » PMID: 35927730

Cardiovascular Outcomes Trials: a Paradigm Shift in the Current Management of Type 2 Diabetes

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Historical concerns about cardiovascular (CV) risks associated with certain glucose-lowering medications gave rise to the introduction of cardiovascular outcomes trials (CVOTs). Initially implemented to help monitor the CV safety of glucose-lowering drugs in patients with T2D, who either had established CVD or were at high risk of CVD, data that emerged from some of these trials started to show benefits. Alongside the anticipated CV safety of many of these agents, evidence for certain sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revealed potential cardioprotective effects in patients with T2D who are at high risk of CVD events. Reductions in 3-point major adverse CV events (3P-MACE) and CV death have been noted in some of these CVOTs, with additional benefits including reduced risks of hospitalisation for heart failure, progression of renal disease, and all-cause mortality. These new data are leading to a paradigm shift in the current management of T2D, with international guidelines now prioritising SGLT2 inhibitors and/or GLP-1 RAs in certain patient populations. However, clinicians are faced with a large volume of CVOT data when seeking to use this evidence base to bring opportunities to improve CV, heart failure and renal outcomes, and even reduce mortality, in their patients with T2D. The aim of this review is to provide an in-depth summary of CVOT data-crystallising the key findings, from safety to efficacy-and to offer a practical perspective for physicians. Finally, we discuss the next steps for the post-CVOT era, with ongoing studies that may further transform clinical practice and improve outcomes for people with T2D, heart failure or renal disease.

Citing Articles

Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor.

Lin C, Hung S, Chen I Int J Gen Med. 2025; 18():135-144.

PMID: 39816640 PMC: 11734502. DOI: 10.2147/IJGM.S497664.


Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side.

Abdelrahman A, Awad A, Hasan I, Abdel-Rahman E J Clin Med. 2025; 13(24.

PMID: 39768655 PMC: 11677827. DOI: 10.3390/jcm13247732.


Use of Cardioprotective Adjuncts in Type 1 Diabetes.

Greenfield J, Frampton R, Millard K, Snaith J Diabetes Ther. 2025; 16(2):145-148.

PMID: 39760824 PMC: 11794932. DOI: 10.1007/s13300-024-01687-3.


Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.

Shah V, Agesen R, Bardtrum L, Christiansen E, Snaith J, Greenfield J J Diabetes Sci Technol. 2024; 19(2):321-331.

PMID: 39717993 PMC: 11669135. DOI: 10.1177/19322968241305647.


SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.

Morciano C, Gugliandolo S, Capece U, Giuseppe G, Mezza T, Ciccarelli G Cardiovasc Diabetol. 2024; 23(1):449.

PMID: 39702365 PMC: 11660748. DOI: 10.1186/s12933-024-02539-x.


References
1.
Uthman L, Baartscheer A, Bleijlevens B, Schumacher C, Fiolet J, Koeman A . Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na/H exchanger, lowering of cytosolic Na and vasodilation. Diabetologia. 2017; 61(3):722-726. PMC: 6448958. DOI: 10.1007/s00125-017-4509-7. View

2.
Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

3.
Sarafidis P, Ferro C, Morales E, Ortiz A, Malyszko J, Hojs R . SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019; 34(2):208-230. DOI: 10.1093/ndt/gfy407. View

4.
White Jr J . A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2015; 27(2):82-6. PMC: 4522877. DOI: 10.2337/diaspect.27.2.82. View

5.
Cherney D, Cosentino F, Dagogo-Jack S, McGuire D, Pratley R, Frederich R . Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. Clin J Am Soc Nephrol. 2021; 16(9):1345-1354. PMC: 8729577. DOI: 10.2215/CJN.01130121. View